Pfizer: Sun Setting On Blockbuster Model
This article was originally published in The Pink Sheet Daily
Industry execs chart move away from “bull’s eye” toward risk sharing.
You may also be interested in...
Pharma has rarely pursued one-size-fits-all strategies, instead segmenting disease categories or patient groups, an effort personalized medicine can only render more relevant and meaningful, exec says.
Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.